Royalty Pharma (MEX:RPRX) Total Assets : MXN380,047 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Royalty Pharma Total Assets?

Royalty Pharma's Total Assets for the quarter that ended in Dec. 2024 was MXN380,047 Mil.

During the past 12 months, Royalty Pharma's average Total Assets Growth Rate was 8.60% per year. During the past 3 years, the average Total Assets Growth Rate was 3.80% per year. During the past 5 years, the average Total Assets Growth Rate was 6.10% per year.

During the past 8 years, Royalty Pharma's highest 3-Year average Total Assets Growth Rate was 17.90%. The lowest was 3.80%. And the median was 5.75%.

Total Assets is connected with ROA %. Royalty Pharma's annualized ROA % for the quarter that ended in Dec. 2024 was 4.72%. Total Assets is also linked to Revenue through Asset Turnover. Royalty Pharma's Asset Turnover for the quarter that ended in Dec. 2024 was 0.03.

Royalty Pharma Total Assets Historical Data

The historical data trend for Royalty Pharma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Total Assets Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

318,675.53

359,320.46

327,795.33

278,069.60

380,047.48

Royalty Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Assets	Get a 7-Day Free Trial															278,069.60	267,712.30	323,470.35	355,257.16	380,047.48

Royalty Pharma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Royalty Pharma's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	215697.282	+	164350.195
	=	380,047

Royalty Pharma's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2024 )	+	Total Liabilities (Q: Dec. 2024 )
	=	215697.282	+	164350.195
	=	380,047

Royalty Pharma (MEX:RPRX) Total Assets Explanation

Total Assets is connected with ROA %.

Royalty Pharma's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %	=	Net Income (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	17369.796	/	( (355257.158	+	380047.477)	/ 2 )
	=	17369.796	/	367652.3175
	=	4.72 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Royalty Pharma's Asset Turnover for the quarter that ended in Dec. 2024 is

	Asset Turnover
=	Revenue (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
=	12380.799	/	( (355257.158	+	380047.477)	/ 2 )
=	12380.799	/	367652.3175
=	0.03

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Royalty Pharma Total Assets Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (MEX:RPRX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

RPRX:USA RPD:Germany

Address

110 East 59th Street, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.